Email: cspc@cspc.cn
News
July 27, 2026
Share:
Previous: VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2062 INJECTION FOR THE TREATMENT OF ADULT ESSENTIAL HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE
Next: VOLUNTARY ANNOUNCEMENT - PALIPERIDONE PALMITATE INJECTION RECEIVES MARKETING APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us